Description
EU5 Conjugate Vaccine Market
Conjugate Vaccine is a type of vaccine that contains bacterial capsular polysaccharide, attached to a protein to enhance immunogenicity and protect against invasive diseases. EU5 is one of the most prominent markets for conjugate vaccines.
The U.K. was the first country to introduce MenB-4C into their National Infant Immunization Program (2015). In all EU/EEA countries, Hib vaccination has been part of the immunization programs, since 2010, and high coverage has been sustained.
Market Segmentation:
o Based on disease indication, the market is segmented into pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal and others. The highest penetration among paediatrics is that of the DTP vaccine.
o Based on end user, the market is segmented into pediatric and adult.
Key growth factors:
The EU5 is projected to have positive growth during the forecasted period. A higher number of vaccination programs by the governments, increase in geriatric population, government initiatives and increase in research and development activities together propel the growth of this market. Germany will grow at a considerable rate over the coming years owing to increasing government initiatives which offer medical advice for the vaccination of children. Rising prevalence of infectious diseases and focused product development will fuel industry expansion.
Threats and key players:
o The EU5 conjugate vaccine market is expected to grow at a constant pace. Vaccine shortages, low access and stringent regulations are some of the challenges faced by this market which need to be addressed to achieve smooth growth.
o Major conjugate vaccine providers operating in the market are GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.
What’s covered in the report?
1. Overview of the EU5 conjugate vaccine market
2. Market drivers and challenges in the EU5 conjugate vaccine market
3. Market trends in the EU5 conjugate vaccine market
4. Historical, current and forecasted market size data for EU5 based on disease indication (pneumococcal, haemophilus influenza type b, diphtheria-tetanus-pertussis, meningococcal conjugate vaccines) – by revenue and by volume
5. Historical, current and forecasted market size data for EU5 based on end user (pediatric and adult conjugate vaccines) – by revenue and by volume
6. Analysis of the competitive landscape and profiles of major companies operating in the EU5 market
Why buy?
o Understand the demand for conjugate vaccines to determine the viability of the market
o Develop strategies based on the drivers and trends for each of the segments
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed
o Recognize the key competitors of this market and respond accordingly
o Identify the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth
o Define the competitive positioning by comparing the products and services with the key players in the market
